Overview

• Novo Nordisk's Wegovy led to 9.6% weight loss in women with HFpEF, compared to 7.2% in men.
• Both sexes saw similar improvements in heart failure symptoms despite the weight loss disparity.
• The study involved 1,145 participants and was presented at the American Diabetes Association's meeting.
• HFpEF accounts for about half of heart failure cases and is especially common among overweight women.
• Further research is needed to understand why greater weight loss in women does not translate to better heart outcomes.